Merck's Rosenblatt ponders innovation investment's 'grand experiment'

There is a grand experiment currently underway, triggered initially by the 2008 economic downturn, with drug makers having to decide whether to plunk their money down on the side of innovative technologies – gambling between hitting the jackpot or going bust – or to pull back and play it safe, said Merck Chief Medical Officer Dr Michael Rosenblatt.